Education

PhD, Tsinghua University (Beijing, China), 2019

BS, Tsinghua University (Beijing, China), 2011

Research Interest

Su lab studies the molecular mechanisms of early dissemination, tumor dormancy, and drug resistance in prostate cancer bone metastases and develops novel targeted protein degradation tools (such as PROTACs) to fight against undruggable therapeutic proteins in cancers.

Teaching Interest

Cancer metastases, Emerging targeted protein degradation techniques.

Awards & Honors

2024, Selected Attendee for 2024 NCI-funded workshop on “Big Data Training for Cancer Research” (BigCARE), with travel award.

2021, Outstanding Post-Doctoral Fellow in Cancer Biology at The University of Toledo.

2016, Excellent PhD student in School of Life Sciences, Tsinghua University.

2011, Excellent Graduate of Tsinghua University (TOP 2% among 3000 graduates).

Publications

Liu R#, Zhao Y#, Su S#, Kwabil A, Njoku PC, Yu H, Li X. Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces. Cancer Lett. 2024 Jun 1;591:216899. doi: 10.1016/j.canlet.2024.216899. Epub 2024 Apr 21. Review. PubMed PMID: 38649107. #Co-First Author

Liu R#, Su S#, Xing J, Liu K, Zhao Y, Stangis M, Jacho DP, Yildirim-Ayan ED, Gatto-Weis CM, Chen B, Li X. Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase. J Exp Clin Cancer Res. 2023 Oct 11;42(1):264. doi: 10.1186/s13046-023-02849-0. PubMed PMID: 37821954; PubMed Central PMCID: PMC10566127. #Co-First Author

Zhao Y, Su S, Li X. Parathyroid Hormone-Related Protein/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis. Cancers (Basel). 2023 Mar 26;15(7). doi: 10.3390/cancers15071982. Review. PubMed PMID: 37046642; PubMed Central PMCID: PMC10093484.

Su S, Cao J, Meng X, Liu R, Vander Ark A, Woodford E, Zhang R, Stiver I, Zhang X, Madaj ZB, Bowman MJ, Wu Y, Xu HE, Chen B, Yu H, Li X. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases. Cancer Lett. 2022 Jan 28;525:170-178. doi: 10.1016/j.canlet.2021.10.042. Epub 2021 Nov 6. PubMed PMID: 34752846; PubMed Central PMCID: PMC9669895.

Su S, Li X. Dive into Single, Seek Out Multiple: Probing Cancer Metastases via Single-Cell Sequencing and Imaging Techniques. Cancers (Basel). 2021 Mar 3;13(5). doi: 10.3390/cancers13051067. Review. PubMed PMID: 33802312; PubMed Central PMCID: PMC7959126.

Su S, Yang Z, Gao H, Yang H, Zhu S, An Z, Wang J, Li Q, Chandarlapaty S, Deng H, Wu W, Rao Y. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 22;62(16):7575-7582. doi: 10.1021/acs.jmedchem.9b00871. Epub 2019 Aug 2. PubMed PMID: 31330105; PubMed Central PMCID: PMC6790125.

An Z, Lv W, Su S, Wu W, Rao Y. Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein Cell. 2019 Aug;10(8):606-609. doi: 10.1007/s13238-018-0602-z. PubMed PMID: 30603959; PubMed Central PMCID: PMC6626596.

Zhao Q, Lan T, Su S, Rao Y. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun (Camb). 2019 Jan 2;55(3):369-372. doi: 10.1039/c8cc07813k. PubMed PMID: 30540295.

Ding Y#, Su S#, Tang W, Zhang X, Chen S, Zhu G, Liang J, Wei W, Guo Y, Liu L, Chen YG, Wu W. Enrichment of the β-catenin-TCF complex at the S and G2 phases ensures cell survival and cell cycle progression. J Cell Sci. 2014 Nov 15;127(Pt 22):4833-45. doi: 10.1242/jcs.146977. Epub 2014 Sep 18. PubMed PMID: 25236602. #Co-First Author

Su S, Wu W. Regulation of target gene transcription by Wnt/β-catenin signaling. Scientia Sinica Vitae. 2014; (10):1029-1042.

Grant Funding

DOD PCRP/W81XWH-22-PCRP-EHDA/PC220043 01/01/2023-12/31/2024

Title: A CLOUD (CRISPR-Mediated Loci-Specific Unbiased Discovery) Atlas of Regulatory Binding Proteins for Driver Genes in Prostate Cancer Bone Metastases

Role: Principal Investigator

DOD PCRP/HT9425-23-PCRP-EHDA/PC230068 04/01/2024-03/31/2026

Title: Dabber: D-type peptide grabber for degradation of undruggable transcription factors in lethal prostate cancer

Role: Principal Investigator

DOD PCRP/HT9425-23-PCRP-EHDA/PC230104 01/01/2024-12/31/2025

Title: PROTAC for PTH1R to treat prostate cancer metastases

Role: Co-Investigator